trending Market Intelligence /marketintelligence/en/news-insights/trending/uxvhtmrrsmm2pkcuzpyr4q2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Akebia Therapeutics plans $85M common stock offering

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Akebia Therapeutics plans $85M common stock offering

Akebia Therapeutics Inc. plans to sell $85 million of its common shares in an underwritten public offering.

The company also plans to give the underwriter an option to buy up to an additional $12.8 million of shares.

Akebia plans to use the net proceeds for the continued clinical development and optimization of the vadadustat program, including pre-commercial planning activities, and the remainder for working capital, business development and other general corporate purposes.

Morgan Stanley is acting as sole book-running manager for the offering.